C4 Therapeutics, Inc.
A biopharmaceutical company developing targeted protein degradation medicines, a technology that harnesses the body's own protein-disposal machinery to destroy disease-causing proteins. Its lead programs target cancers and other serious diseases. The company was founded in 2015 as a spinout from Dana-Farber Cancer Institute, and its name reflects its focus on the "C4" family of E3 ligase enzymes that tag proteins for destruction.
Granted 5.3K
Granted 5.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Anderson Kenneth CarlDirector · 2 transactions | — | 525.4K | 5.3K | — | — |
| Grogan Donna RoyDirector · 1 transaction | +8.1% | 71.5K | 5.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.